Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Alpuente

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Current Opinion in Neurology|April 6, 2019
How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspectiveMarta Torres-Ferrus, Alicia Alpuente, Patricia Pozo-Rosich
Neurology|August 11, 2022
Association of a Cyclical Migraine Phenotype With Disease Progression: A 1-Year Time Series AnalysisVictor J Gallardo, Alicia Alpuente, Patricia Pozo-Rosich
Handbook of Clinical Neurology|February 2, 2024
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine preventionEdoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, et al.
Current Opinion in Neurology|March 26, 2024
The state of art on the use of patient reported outcomes in migraineAlicia Alpuente, Marta Torres-Ferrus, Edoardo Caronna, et al.
Nature Reviews. Neurology|August 19, 2024
Insights from 25 years of onabotulinumtoxinA in migraine - mechanisms and managementPatricia Pozo-Rosich, Alicia Alpuente, Stephen D Silberstein, et al.
Headache|August 7, 2021
Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenariosEdoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, et al.
The Journal of Headache and Pain|July 13, 2020
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinAMarta Torres-Ferrus, Victor José Gallardo, Alicia Alpuente, et al.
Journal of Neurology|July 20, 2021
Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainabilityEdoardo Caronna, Victor José Gallardo, Alicia Alpuente, et al.
European Journal of Neurology|March 17, 2021
Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence studyAlicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
Headache|November 2, 2022
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative reviewJavier A Membrilla, Marta Torres-Ferrus, Alicia Alpuente, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Opinion in Neurology|April 6, 2019
How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspectiveMarta Torres-Ferrus, Alicia Alpuente, Patricia Pozo-Rosich
Neurology|August 11, 2022
Association of a Cyclical Migraine Phenotype With Disease Progression: A 1-Year Time Series AnalysisVictor J Gallardo, Alicia Alpuente, Patricia Pozo-Rosich
Handbook of Clinical Neurology|February 2, 2024
CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine preventionEdoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, et al.
Current Opinion in Neurology|March 26, 2024
The state of art on the use of patient reported outcomes in migraineAlicia Alpuente, Marta Torres-Ferrus, Edoardo Caronna, et al.
Nature Reviews. Neurology|August 19, 2024
Insights from 25 years of onabotulinumtoxinA in migraine - mechanisms and managementPatricia Pozo-Rosich, Alicia Alpuente, Stephen D Silberstein, et al.
Headache|August 7, 2021
Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenariosEdoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, et al.
The Journal of Headache and Pain|July 13, 2020
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinAMarta Torres-Ferrus, Victor José Gallardo, Alicia Alpuente, et al.
Journal of Neurology|July 20, 2021
Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainabilityEdoardo Caronna, Victor José Gallardo, Alicia Alpuente, et al.
European Journal of Neurology|March 17, 2021
Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence studyAlicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
Headache|November 2, 2022
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative reviewJavier A Membrilla, Marta Torres-Ferrus, Alicia Alpuente, et al.
Pageof 6